Home › NCT06162403
Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study
Recruiting
Who can join
Ages 18 to 85 · All sexes
Full eligibility criteria
Inclusion Criteria: * Participants diagnosed with chronic (≥90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at Pain Management Center at MD Anderson Cancer Center * Participants reports baseline pain ≥ 4 (0-10 scale, NRS) * Participants between ages 18-85 years old * Participants who have completed chemotherapy within the previous year at the time of enrollment Exclusion Criteria: * Participants with cognitive dysfunction * Participants with recent history (\<6 months) of drug or alcohol abuse * Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection * Participants with allergies to local anesthesia, steroids, or adhesives * Participants with conditions that conflict with the SPRINT PNS System Indications for Use, including Contraindications and Warnings.
About the study
To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.
What is being tested
- Peripheral Nerve Stimulation (other)
Sponsor: M.D. Anderson Cancer Center · Participants: 10 · Started: Feb 22, 2024
Contact the study team
- Saba Javed, MD · Phone: (713) 792-9530
Official record on ClinicalTrials.gov — NCT06162403
Locations in the U.S.
| Texas | MD Anderson Cancer Center, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.